Ładuje się......
PROTAC Technology: Opportunities and Challenges
[Image: see text] PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer...
Zapisane w:
| Wydane w: | ACS Med Chem Lett |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Chemical
Society
2020
|
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7073876/ https://ncbi.nlm.nih.gov/pubmed/32184950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00597 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|